Investigating the mechanisms of lapatinib resistance in HER2-amplified gastric cancer patients may not only provide new therapeutic strategies for HER2-positive patients but also potentially improve their sensitivity to lapatinib and trastuzumab. The gene discussed is ERBB2; the disease is gastric cancer.